Basilea Pharmaceutica

Basilea Pharmaceutica is a Swiss biopharmaceutical company focused on developing and commercializing innovative drugs to address severe bacterial and fungal infections. Their core expertise lies in anti-infectives, specifically antifungals and antibiotics. The company has successfully brought two anti-infective drugs to the market: Cresemba, an antifungal for the treatment of invasive mold infections, and Zevtera, an antibiotic for treating bacterial infections, primarily pneumonia. Basilea boasts a diverse portfolio of preclinical and clinical anti-infective assets and is listed on the SIX Swiss Exchange.

Their mission centers around finding solutions for patients battling serious and life-threatening conditions, with a commitment to both research and development and the commercialization of their products. The company is actively expanding their R&D pipeline through internal initiatives and partnerships, seeking to establish itself as a leading force in the anti-infective space.

Basilea Pharmaceutica values its employees and offers a flexible work environment. They believe in a "personal touch" in all interactions, from the initial interview to retirement. They offer opportunities for employees to work on a variety of projects, allowing them to develop their skills and knowledge. Employees have the freedom to make decisions and contribute meaningfully to the company's goals. This results in a fast-paced work environment where employees are able to grow and learn quickly.

Basilea Pharmaceutica offers competitive remuneration and a range of benefits to its employees. These include an attractive pension plan, personalized training courses, and other benefits. The company emphasizes its commitment to its employees and believes that a supportive work environment is crucial to making a difference for patients.

Basilea Pharmaceutica is a commercial-stage biopharmaceutical company focused on developing innovative medicines to address the medical needs of patients with severe bacterial and fungal infections. They strive to become a leading provider of innovative medicines in the anti-infectives space by discovering, developing, and commercializing these drugs, contributing to global health priorities with expertise, care, and persistence.

Basilea Pharmaceutica promotes a culture that emphasizes personal interaction, teamwork, and tenacity. The company believes in empowering employees to make an impact by working on diverse projects and offering the freedom to make decisions. They foster a collaborative environment where employees are encouraged to develop their skills and knowledge through fast-paced projects and work with fellow driven professionals.

Basilea Pharmaceutica believes that diversity, equity, and inclusion are fundamental to their success. They recognize that a diverse workforce, including those from underrepresented groups, enriches their perspectives and strengthens their problem-solving abilities. They have conducted a materiality analysis to identify key ESG topics, including diversity, equality, and inclusion, which are central to their ESG strategy. This commitment is reflected in their efforts to promote a culture of inclusivity and respect within the company, as well as their active pursuit of measurable progress against these goals.